Effect of Menopausal Hormone Therapy on Immune System Parameters

Optimization of Management Tactics for Postmenopausal Patients in Need of Menopausal Hormone Therapy, Taking Into Account the Effect on the Parameters of the Immune System

The objective of the study is to evaluate the effect of menopausal hormone therapy on the parameters of the immune system. To do this, patients took blood to assess the immune status before the start of therapy and after 3 months.

An additional task is to assess the content of blood sex hormones before the start of therapy and after 3 months.

A study of 60 perimenopausal and postmenopausal patients was included. The cohort was divided into groups depending on the treatment regimen.

Group 1 (n=20) received transdermal menopausal hormone therapy (MHT). Group 2 (n=20) received oral MHT.

Inclusion Criteria:

• age from 45 to 59;
• phase of reproductive aging - perimenopause, postmenopause or surgical menopause (ovariectomy);
• indications for prescribing MHT

Exclusion Criteria:

1. Absolute contraindications to MHT:

   • Bleeding from the genital tract of unknown origin
   • Breast and endometrial cancer
   • Acute hepatitis
   • Acute deep vein thrombosis
   • Acute thromboembolism
   • Cutaneous porphyria

2. Obesity;

3. HIV infection and other congenital and acquired immunodeficiencies;

4. Systemic connective tissue diseases;

5. Oncological diseases in history;

6. History of chemotherapy and/or radiation therapy;

7. Autoimmune diseases;

8. Acute diseases and exacerbation of chronic diseases during the last 3 months;

9. Reception of immunomodulatory drugs during the last 3 months.